Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Day One Biopharmaceuticals, Inc. (DAWN) reported a Q4 loss of $0.69 per share, which was wider than the Zacks Consensus Estimate of a $0.35 loss. However, the company exceeded revenue expectations.
February 26, 2025 | 12:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Day One Biopharmaceuticals reported a Q4 loss of $0.69 per share, missing the Zacks Consensus Estimate of a $0.35 loss. Despite this, the company exceeded revenue expectations.
The reported loss per share was significantly higher than expected, which is typically negative for stock prices. However, the company exceeded revenue expectations, which could mitigate some negative impact. Overall, the missed EPS is likely to weigh more heavily in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100